Absci

Eli Lilly Invests $40M in Absci, Signaling Strategic Expansion into AI-Driven Hair Loss and Endometriosis Therapies

Eli Lilly has invested $40 million in AI startup Absci, leading a $100 million funding round. This strategic move signals Lilly's expansion into aesthetic medicine, specifically hair loss treatments, while also targeting endometriosis. For decision-makers, this highlights a major pharmaceutical player leveraging AI for pipeline diversification, impacting future R&D, procurement strategies, and competitive dynamics in these therapeutic markets.